Skip Ribbon Commands
Skip to main content
Sign In
MIT Sloan > LearningEdge > Strategy > Eli Lilly: Recreating Drug Discovery for the 21st Century
Eli Lilly- Recreating Drug Discovery
Authors
Rebecca M. Henderson and Cate Reavis
Abstract
“The challenge for us as an industry, as a company, is to move from a blockbuster model to a targeted model… . We need a better value proposition than today.” – Sydney Taurel, CEO, Eli Lilly (The New York Times, July 3, 2005)
As a result of new science and untenable cost structures, in 2007 Eli Lilly was preparing for the future with a long-range strategy involving the development of tailored drugs.
Learning Objective
To explore the issues inherent in trying to implement a significantly different strategy—“tailored therapeutics”—without investing in significant organizational change.
Instructor Note
This is a follow-on case to “Eli Lilly’s Project Resilience: Anticipating the Future of the Pharmaceutical Industry,” although it also can be taught as a stand-alone case.
Could be taught in the following course(s)
strategy, pharmaceuticals